Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
Explore linked clinical trials.48 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM | Nutritional and Metabolic Diseases, amyloidosis, metabolic disease, proteostasis deficiencies | Active, not recruiting | Phase 2 | 2026-10-07 | NCT07213583 | |
| Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) | Chronic Disease, Disease Attributes, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, IgA glomerulonephritis, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Urination Disorders, Urogenital Diseases, Urological Manifestations, autoimmune disease, chronic renal failure syndrome, glomerulonephritis, immune system disorder, kidney disorder, kidney failure, nephritis, proteinuria, urinary system disorder | Active, not recruiting | Phase 3 | 2026-10-02 | NCT06291376 | |
| Paroxysmal Nocturnal Hemoglobinuria in ESUS & ETUS | Cytopenia, Embolism and Thrombosis, Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, Intracranial Embolism and Thrombosis, Thromboembolism, anemia, bone marrow disorder, brain disorder, brain ischemia, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, hematologic disorder, hemolytic anemia, intracranial thrombosis, myelodysplastic syndrome, nervous system disorder, paroxysmal nocturnal hemoglobinuria, transient ischemic attack, vascular disorder | Active, not recruiting | Not stated | 2026-09-18 | NCT03329365 | |
| Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, generalized myasthenia gravis, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Recruiting | Phase 3 | 2026-09-11 | NCT07596784 | |
| Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Study of Ravulizumab in Chinese Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD) | CNS demyelinating autoimmune disease, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, nervous system disorder, neuromyelitis optica, optic nerve disorder, optic neuritis | Recruiting | Phase 3 | 2026-09-11 | NCT07557420 | |
| Registry of Patients With Hypophosphatasia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, hereditary disease, hypophosphatasia, inborn errors of metabolism, inborn metal metabolism disorder, metabolic disease | Enrolling by invitation | Not stated | 2026-09-04 | NCT02306720 | |
| An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy | Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Not yet recruiting | Phase 3 | 2026-08-28 | NCT07789483 | |
| ALXN2350 in Adult Participants With BAG3-Associated Dilated Cardiomyopathy | BAG3 Mutation Associated Dilated Cardiomyopathy | Recruiting | Phase 1 / Phase 2 | 2026-08-28 | NCT07218887 | |
| Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation | AMR; Antibody-Mediated Rejection; Biopsy-proven Histologic Scores; Kidney Transplantation | Active, not recruiting | Phase 2 | 2026-08-11 | NCT06744647 | |
| Study of ALXN2220 Versus Placebo in Adults With ATTR-CM | Nutritional and Metabolic Diseases, amyloidosis, metabolic disease, proteostasis deficiencies | Active, not recruiting | Phase 3 | 2026-08-10 | NCT06183931 | |
| Study of Ravulizumab in Pediatric Participants With Primary IgAN | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Hemic and Lymphatic Diseases, Hemorrhage, IgA glomerulonephritis, Male Urogenital Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Skin Manifestations, Skin and Connective Tissue Diseases, Urination Disorders, Urogenital Diseases, Urological Manifestations, autoimmune disease, blood coagulation disease, cardiovascular disorder, glomerulonephritis, hematologic disorder, hemorrhagic disease, immune system disorder, immunoglobulin A vasculitis, kidney disorder, nephritis, proteinuria, purpura, skin disorder, skin vascular disease, type III hypersensitivity disease, urinary system disorder, vascular disorder, vascular hemostatic disease, vasculitis | Recruiting | Phase 3 | 2026-07-30 | NCT07024563 | |
| ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program | Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Cerebral Small Vessel Diseases, Ceroid Lipofuscinosis, Neuronal, 2, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Disease Attributes, Fabry disease, GM1 gangliosidosis, Gangliosidoses, Gaucher disease, Hemic and Lymphatic Diseases, Hereditary Central Nervous System Demyelinating Diseases, Infant, Newborn, Diseases, Leukoencephalopathies, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Lysosomal Storage Diseases, Nervous System, Mucopolysaccharidosis III, Neurobehavioral Manifestations, Neurologic Manifestations, Niemann-Pick disease, Niemann-Pick disease type C, Nutritional and Metabolic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Rare Diseases, Skin and Connective Tissue Diseases, Sulfatidosis, Wolman disease, X-linked disease, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrotendinous xanthomatosis, cerebrovascular disorder, cholesteryl ester storage disease, connective tissue disorder, cutaneous mucinosis, demyelinating disease, hereditary disease, histiocytosis, inborn carbohydrate metabolic disorder, inborn errors of metabolism, inherited neurodegenerative disorder, intellectual disability, lymphatic system disorder, lysosomal lipid storage disorder, lysosomal storage disease, metabolic disease, metachromatic leukodystrophy, mucopolysaccharidosis, mucopolysaccharidosis type 2, mucopolysaccharidosis type 4, mucopolysaccharidosis type 6, mucopolysaccharidosis type 7, nervous system disorder, non-Langerhans cell histiocytosis, sphingolipidosis, vascular disorder, xanthomatosis | Enrolling by invitation | Not stated | 2026-07-28 | NCT05368038 | |
| Acceptability and Safety of MR-C-014 in Persons With Neuromyelitis Optica Spectrum Disorder | CNS demyelinating autoimmune disease, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, nervous system disorder, neuromyelitis optica, optic nerve disorder, optic neuritis | Enrolling by invitation | Not applicable | 2026-07-06 | NCT06374264 | |
| A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. | Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Recruiting | Phase 1 / Phase 2 | 2026-07-02 | NCT07081646 | |
| A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, hematologic disorder, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Active, not recruiting | Phase 3 | 2026-07-02 | NCT04504825 | |
| Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD | CNS demyelinating autoimmune disease, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, nervous system disorder, neuromyelitis optica, optic nerve disorder, optic neuritis | Active, not recruiting | Phase 2 / Phase 3 | 2026-06-24 | NCT05346354 | |
| Phase 3 Study of ALXN1850 Versus Placebo in Adolescent and Adult Participants With HPP Who Have Not Previously Been Treated With Asfotase Alfa | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Nutritional and Metabolic Diseases, hereditary disease, hypophosphatasia, inborn errors of metabolism, inborn metal metabolism disorder, metabolic disease | Active, not recruiting | Phase 3 | 2026-06-22 | NCT06079281 | |
| Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN) | Primary Membranous Nephropathy | Recruiting | Phase 2 | 2026-06-18 | NCT07157787 | |
| Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation | Delayed Graft Function, Pathologic Processes, Pathological Conditions, Signs and Symptoms | Recruiting | Phase 3 | 2026-06-18 | NCT06830798 | |
| Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies | CNS demyelinating autoimmune disease, acute transverse myelitis, autoimmune disease, autoimmune disorder of the nervous system, cranial nerve neuropathy, demyelinating disease, eye disorder, immune system disorder, nervous system disorder, neuromyelitis optica, optic nerve disorder, optic neuritis | Recruiting | Not stated | 2026-06-18 | NCT05966467 | |
| A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNH | Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, Hemolysis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, anemia, bone marrow disorder, hematologic disorder, hemolytic anemia, myelodysplastic syndrome, paroxysmal nocturnal hemoglobinuria | Active, not recruiting | Phase 3 | 2026-06-18 | NCT05389449 | |
| Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis | Neoplasms by Site, Paraneoplastic Syndromes, Nervous System, autoimmune disease, autoimmune disorder of the nervous system, immune system disorder, myasthenia gravis, neoplasm, nervous system disorder, neurodegenerative disease, neuromuscular disease, neuromuscular junction disease, paraneoplastic syndrome | Active, not recruiting | Phase 3 | 2026-06-17 | NCT05556096 | |
| A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES) | Blood Protein Disorders, Hemic and Lymphatic Diseases, Immunoglobulin Light-chain Amyloidosis, Neoplasms by Histologic Type, Nutritional and Metabolic Diseases, amyloidosis, hematologic disorder, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, metabolic disease, monoclonal gammopathy, neoplasm, plasma cell neoplasm, proteostasis deficiencies | Active, not recruiting | Phase 3 | 2026-06-17 | NCT04512235 | |
| Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis | Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, cardiovascular disorder, immune system disorder, necrotizing vasculitis, skin disorder, skin vascular disease, vascular disorder, vasculitis | Recruiting | Phase 2 | 2026-06-16 | NCT07160608 | |
| A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease) (BAG3 DCM) | Cardiomegaly, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, cardiomyopathy, cardiovascular disorder, dilated cardiomyopathy, heart disorder, hereditary disease, laminopathy | Active, not recruiting | Not stated | 2026-06-12 | NCT05981092 |